āshibio Moves Forward with Clinical Trial
āshibio announced the dosing of the first participant in its Phase 2/3 clinical trial for its lead candidate, andecaliximab.
Cogwear Featured as a Startup to Watch in 2025
Cogwear was listed as one of PHL Inno’s Startups to Watch.
Interius Ranks in Top Ten of Capital Raises by Philadelphia Startups in 2024
Interius was recognized in the Philadelphia Business Journal’s “PHL Inno 2024 in Review” as one of the top Philadelphia-area startups raising capital last year.
Penn Spinout Gemma Therapeutics Raises $34 million to Develop Gene Therapies for Rare Diseases
Gemma Bio raised $34 million in a seed round led by Double Point Ventures, Bioluminescence Ventures and Earlybird Venture Capital.
Mitchell Lab Discovers Siloxane-Enhanced Nanoparticles and Refines LNPs to Advance mRNA Medicine
A group of researchers at Penn Engineering led by Michael Mitchell, PhD, Associate Professor in Bioengineering, have developed a method to direct lipid nanoparticles (LNPs) to target specific tissues.
Franklin Biolabs Names its First CEO
Franklin Biolabs, a Penn spinout founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, has named Vatsala Naageshwaran as its first chief executive officer.
Ocuphire Pharma Announces Acquisition of Opus Genetics, a Penn startup based on technology developed by Dr. Jean Bennett and colleagues
The merger between Opus and Ocuphire creates a transformative biotech company, renamed Opus Genetics, Inc, which is committed to the development of gene therapies for the treatment of IRDs.
EpiVario Secures Key Patents for Innovative Addiction Treatment
EpiVario, Inc., a Penn spinout co-founded by Shelley Berger, PhD, the Daniel S. Och University Professor at Penn Medicine, announced the issuance to Penn of US Patent No. 12,077,527.
Penn spinout REGENXBIO Presents Positive Data from Phase II Study for Wet AMD Treatment
Penn spinout REGENXBIO, co-founded by James Wilson, MD, PhD, Rose H. Weiss Professor in Penn Medicine, announced positive results from a phase II study for its treatment ABBV-RGX-314.
Interius BioTherapeutics Doses First Patient within vivo CAR T cell therapy
Interius has dosed its first patient in a clinical trial of its lead drug candidate, INT2104, an in vivoCAR T cell therapy that targets B-cell malignancies